{
    "root": "fe4239d0-8003-4b3e-9770-01b21a0dd1d8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Etodolac",
    "value": "20250502",
    "ingredients": [
        {
            "name": "Etodolac",
            "code": "2M36281008",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4909"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "Magnesium Stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "Sodium Starch Glycolate Type A Potato",
            "code": "5856J3G2A2",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "Ferric Oxide Red",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "indications": {
        "text": "carefully consider potential benefits risks etodolac capsules tablets treatment options deciding etodolac capsules tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . etodolac capsules tablets indicated : \u2022for acute long-term management signs symptoms following : 1.osteoarthritis 2.rheumatoid arthritis \u2022for management acute pain",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks etodolac capsules tablets treatment options deciding etodolac capsules tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( ) . observing response initial therapy etodolac capsules tablets , dose frequency adjusted suit individual patient 's needs . adjustment etodolac capsules tablets generally required patients mild moderate renal impairment . etodolac used caution patients , , nsaids , may decrease renal function patients impaired renal function ( , renal effects ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "etodolac tablets , usp 400 mg tablets ( peach , oval shaped , film coated tablet engraved `` t88 `` one side side plain ) bottles 20 , ndc 68788-8673-2 bottles 30 , ndc 68788-8673-3 bottles 60 , ndc 68788-8673-6 bottles 90 , ndc 68788-8673-9 bottles 100 , ndc 68788-8673-1",
    "adverseReactions": "etodolac capsules tablets contraindicated patients known hypersensitivity etodolac ingredients etodolac . etodolac capsules tablets given patients experienced asthma , urticaria , allergic-type taking aspirin nsaids . severe , rarely fatal , anaphylactic-like nsaids reported patients ( , anaphylactoid , pre-existing asthma ) . \u2022in setting coronary artery bypass graft ( cabg ) surgery [ ]",
    "indications_original": "Carefully consider the potential benefits and risks of etodolac capsules and tablets and other treatment options before deciding to use etodolac capsules and tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see     \n                        WARNINGS\n                     ).   \n                  Etodolac Capsules and Tablets are indicated:\n                  \n                     \n                        \u2022For acute and long-term use in the management of signs and symptoms of the following:       \n                           \n                              1.Osteoarthritis\n                           \n                              2.Rheumatoid arthritis\n                        \n                     \n                     \n                        \u2022For the management of acute pain",
    "contraindications_original": "Carefully consider the potential benefits and risks of etodolac capsules and tablets and other treatment options before deciding to use etodolac capsules and tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see     \n                        WARNINGS\n                     ).   \n                  After observing the response to initial therapy with etodolac capsules and tablets, the dose and frequency should be adjusted to suit an individual patient's needs.\n                  Dosage adjustment of etodolac capsules and tablets is generally not required in patients with mild to moderate renal impairment. Etodolac should be used with caution in such patients, because, as with other NSAIDs, it may further decrease renal function in some patients with impaired renal function (see     \n                        WARNINGS, Renal Effects\n                     ).",
    "warningsAndPrecautions_original": "Etodolac Tablets, USP\n                  400 mg tablets (peach, oval shaped, film coated tablet engraved with \"T88\" on one side and other side plain)\n                  \n                     \n                        \u00a0in bottles of 20, NDC 68788-8673-2\n                     \n                        \u00a0in bottles of 30, NDC 68788-8673-3\n                     \n                        \u00a0in bottles of 60, NDC 68788-8673-6\n                     \n                        \u00a0in bottles of 90, NDC 68788-8673-9\n                     \n                        \u00a0in bottles of 100, NDC 68788-8673-1",
    "adverseReactions_original": "Etodolac Capsules and Tablets are contraindicated in patients with known hypersensitivity to etodolac or other ingredients in etodolac.\n                  Etodolac Capsules and Tablets should not be given to patients who have experienced asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see     \n                        WARNINGS, Anaphylactoid Reactions\n                     and     \n                        PRECAUTIONS, Pre-existing Asthma\n                     ).   \n                  \n                     \n                        \u2022In the setting of coronary artery bypass graft (CABG) surgery [see       \n                           Warnings\n                        ]",
    "drug": [
        {
            "name": "Etodolac",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4909"
        }
    ]
}